Hybrid Medical Media Summer Report on” The Status of a Cure for Breast Cancer”.
We are pleased to report that genomics science is making a major impact on breast cancer. 20% Of Breast Cancers are HER2 is over-expressed. HER2 Gene Amplified in Breast Cancer 82% Chance of Relapse. 34% chance of relapse. At The American Society of Clinical Oncology annual meeting in Chicago Roche announced the preliminary success of its
antibody-drug conjugate T-DM1 (trastuzumab emtansine) in a critical Phase III clinical trial. While the exact numbers are not yet available, Roche reports that top-line data from the EMILIA trial showed patients with HER2+ metastatic breast cancer that were treated with T-DM1 displayed a significant increase in progression free survival, as compared to those treated with lapatinib plus Xeloda.
T-DM1 is being developed under a licensing agreement between Roche’s Genentech and Immunogen, and is an exciting example of cutting-edge innovation in antibody-drug conjugate (ADC) development. Early ADCs (such as Seattle Genetics’ Adcetris) delivered chemotherapy directly to cancerous cells, by linking a small molecule chemotherapeutic to an antibody targeted towards a tumor specific marker. In contrast, Roche’s T-DM1 couples ImmunoGen’s cancer killer, DM1, to Genentech’s hugely successful therapeutic antibody Herceptin. In theory, T-DMI should provide the dual action benefits of Herceptin, which binds to the Human Epidermal Growth Factor Receptor 2 (HER2) expressed on the surface of some breast cancer cells. Herceptin binding to HER2 targets the cancer cells for destruction by the immune system, while simultaneously blocking growth-promoting HER2 signaling within the cell. By linking the anticancer compound DM1 to Herceptin, T-DM1 mounts a multi-pronged attack on breast cancer cells that express the HE R2 receptor (HER2+ breast cancer). This is an important strategy in the fight against breast cancer, as it is a disease in which many cellular pathways upregulate to promote tumor cell survival when another pathway is targeted by a cancer drug. Breast cancer can be molecularly inhomogeneous between patients – therefore targeting a therapy towards a certain segment of patients (just as T-DM1 and Herceptin treat HER2+ breast cancer patients) encourages the likelihood of a drug’s success within a given population.
Roche, Immunogen and Genentech are all proudly touting T-DM1’s early success in the EMILIA trial. However, the improved overall progression free survival data presented is only one of the primary trial endpoints, and likely less important than improved overall survival (which requires more mature data). Genentech should be particularly sensitive to the fact that an improvement in progression free survival is not always enough to warrant drug approval. The UK’s National Institute of Health and Clinical
Excellence never approved its blockbuster cancer drug Avastin for the breast cancer indication, and ultimately the FDA withdrew the drug from the US market due a lack of data showing improved overall survival and severe side effects that counteracted the small retardation of disease progression. Avastin was initially approved in the US in 2008 under the FDA’s accelerated approval program, and the FDA may have learned their lesson as they refused to file Genetech’s Biologics License Application for T-DM1 under the same accelerated approval program in 2010.
With this early data from the EMILIA trial, Genentech plans to try again and submit a Biologics License Application to the FDA for T-DM1 for treatment of metastatic HER2+ breast cancer later this year. Additionally, Roche plans to submit a Marketing Authorization Application to the European Medicines Agency. All parties involved seem to be optimistic; however, data demonstrating significant improvement in overall survival compared to current treatments for HER2+ metastatic breast cancer will be critical to the approval of T-DM1 by global regulatory and watchdog agencies. If they manage to fulfill this criterion, this collaboration stands to be extremely lucrative, as Herceptin sales amounted to 5.25 billion CHF in 2011. Following a recent epidemic of counterfeit Avastin in the US, and a loss of nearly 18% in Avastin sales attributed to the FDA’s withdrawal of its breast cancer indication, Roche and Genentech could really use a win.
The better News is that Genomics is on the Clock.
Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is GenNXeix Biotech Semiconductor Sequencing. "Quantum Theory" In Action for Breast Cancer Patients”.
A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a GenNXeix Biotech also 
uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts.GenNXeix Biotech works is a genetic network simulation trained with tumor incidence data from knockout experiments.
GenNXeix Biotech uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.
GenNXeix Biotech used a high-density array of micro-machined wells for biotechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.
HER2 in many patients respond differently. Genomics can be the GPS to extend life in Breast Cancer Patients.
Formalin fixed, paraffin embedded techniques and Her-2 Approximately Where do you really come from? And how can this information Solve Breast Cancer? Approximately 30% of malignant breast cancers demonstrate over amplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based GenNXeix Biotech have demonstrated that they can be used to map DNase (deoxyribonuclease) DNA origins of replication. GenNXeix Biotech Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution for Breast Cancer chemotherapy. Formalin fixed, paraffin embedded techniques and Her-2The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.
The better News is that Genomics is on the Clock.
Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is GenNXeix Biotech Semiconductor Sequencing. "Quantum Theory" In Action for Breast Cancer Patients.
A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA RNA template in the processes of replication and transcription. In association with a GenNXeix Biotech also uses a 
Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts. GenNXeix Biotech works is a genetic network simulation trained with tumor incidence data from knockout experiments.
GenNXeix Biotech uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips. Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.
GenNXeix Biotech used a high-density array of micro-machined wells for biotechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.
HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients Hybrid Medical Media is happy to report.
No comments:
Post a Comment